News Channels

12 Aug 2019 RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6)
10 Aug 2019 Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease
10 Aug 2019 Coordination Pharmaceuticals Announces Enrollment of the First Patient in Phase 1 Study of CPI-200 in Patients With Advanced Tumors
10 Aug 2019 Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
09 Aug 2019 Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
08 Aug 2019 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
08 Aug 2019 89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
08 Aug 2019 Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus
08 Aug 2019 Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
08 Aug 2019 Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
07 Aug 2019 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
07 Aug 2019 Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
07 Aug 2019 Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
07 Aug 2019 Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
07 Aug 2019 Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
07 Aug 2019 Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
07 Aug 2019 Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
06 Aug 2019 Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
06 Aug 2019 Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial
06 Aug 2019 Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up